Current therapies for Parkinson’s disease and related conditions primarily treat symptoms but don’t stop the underlying process causing the disease.
Increasing evidence suggests that toxic clumps of proteins called alpha-synuclein are among the primary drivers of damage to neurons. My team and I developed a synthetic molecule that can block these proteins from clumping and spreading in the brains of mice, ultimately reducing symptoms of disease.
